TBX-2400

TBX-2400: A NEW CLASS OF CELL THERAPY

TBX-2400 Overview

  • TBX-2400 is an allogeneic stem cell product being developed to improve bone marrow transplants.

  • The U.S. FDA has approved TBX-2400’s IND.

  • Treatment includes the infusion of donor hematopoietic stem cells treated with TBX-4000.

Key Milestones

  • Active Phase I/II clinical trial for patients with either AML or Myelofibrosis.

  • US Orphan Drug Designation.

  • US Rare Pediatric Drug Designation.

  • EMA Orphan Drug Designation.

  • EMA Advanced Therapy Medicinal Product Designation.

IMPROVING BONE MARROW TRANSPLANTS

Composed of donor hematopoietic stem cells treated ex vivo for 1 hour with TBX-4000.

Taiga_Graphics_Powerpoint_v1.0-01.png

1. Blood Collection: blood is drawn from the donor in a hospital or clinic in an outpatient setting.

2. Processing: the bone marrow stem cells are separated and treated with Taiga's TBX-4000 protein.

3. Treatment: the treated cells are then given to the patient.

TBX-2400: BETTER, FASTER, AFFORDABLE

Issues with today's allogenetic BMTs

BMT_edited.jpg
BMT_edited.jpg

TAIGA's TBX-2400

taiga bmt_edited.jpg